Clinical trial
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe…
NCT00090116 · Forest Laboratories, Industry · Completed
Key facts
| NCT number | NCT00090116 |
|---|---|
| Title | The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease |
| Official title | A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type |
| Lead sponsor | Forest Laboratories, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Neramexane |
| Enrollment | 400 |
| Start date | Mar 1, 2003 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Aug 26, 2004 |
| Last update posted | Mar 5, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: